Publisher Correction: B cell therapy in ANCA-associated vasculitis: current and emerging treatment options.
In the section 'Combining B cell-targeted therapies' in the originally published version of this article, the 24-week interim analysis for the CALIBRATE study was incorrectly given as the 2- to 4-week interim analysis. This error has now been corrected in the HTML and PDF versions of the manuscript.
| Published in: | Nature Reviews Rheumatology Vol. 14; no. 12; pp. 741 - 742 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Published: |
Springer Nature
Dec2018
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=133151954&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 133151954 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17594790 8UU9 jtl: Nature Reviews Rheumatology issn: 17594790 maglogo: N pubinfo: dt: Dec2018 vid: 14 iid: 12 pid: 2579 pub: Springer Nature place: Dordrecht, <Blank> artinfo: ui: 133151954 133151954 NLM30390047 10.1038/s41584-018-0116-3 NLM30390047 133151954 ppf: 741 ppct: 1 formats: tig: atl: Publisher Correction: B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. aug: au: McClure, Mark Gopaluni, Seerapani Jayne, David Jones, Rachel affil: Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, Cambridge University Hospitals, Cambridge, UK sug: ab: In the section 'Combining B cell-targeted therapies' in the originally published version of this article, the 24-week interim analysis for the CALIBRATE study was incorrectly given as the 2- to 4-week interim analysis. This error has now been corrected in the HTML and PDF versions of the manuscript. pubtype: Academic Journal doctype: Journal Article ougenre: Unknown language: English refInfo: holdings: @attributes: islocal: N |
|---|